Immune-checkpoint inhibitors and chimeric antigen receptor (CAR) T cells are
revolutionizing oncology and haematology practice. With these and other immunotherapies …

Interleukin-12 (IL-12) is a potent, pro-inflammatory type 1 cytokine that has long been
studied as a potential immunotherapy for cancer. Unfortunately, IL-12's remarkable …

Interleukin-12 is considered a potent agent to enhance antitumor immune responses. It
belongs to a family of heterodimeric cytokines with key roles in the up-regulation and down …

Purpose Vitiligo-like depigmentation in patients with melanoma may be associated with
more favorable clinical outcome. We conducted a systematic review of patients with stage III …

During the past two decades, interleukin-12 (IL-12) has emerged as one of the most potent
cytokines in mediating antitumor activity in a variety of preclinical models. Through …

Abstract Interleukin 12 (IL-12) seemed to represent the ideal candidate for tumor
immunotherapy, due to its ability to activate both innate (NK cells) and adaptive (cytotoxic T …

Simple Summary Innate immune natural killer (NK) cells are capable of killing metastatic
cancer cells without activation by antigen-presenting cells beforehand. The cytotoxic effects …

Interleukin 12 (termed IL-12p70 and commonly designated IL-12) is an important
immunoregulatory cytokine that is produced mainly by antigen-presenting cells. The …

Abstract Interleukin-12 (IL-12) is a heterodimeric protein, first recovered from EBV-
transformed B cell lines. It is a multifunctional cytokine, the properties of which bridge innate …

Abstract Interleukin-12 (IL-12) was the first member of the IL-12 family of cytokines to be
identified and has therefore become its eponym. It is a heterodimeric protein of two subunits …